Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
Sichuan Kelun Pharmaceutical Co Ltd
Free Cash Flow
Sichuan Kelun Pharmaceutical Co Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
|
Free Cash Flow
¥2.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Free Cash Flow
¥4.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Free Cash Flow
¥1B
|
CAGR 3-Years
47%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
21%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Free Cash Flow
¥5.5B
|
CAGR 3-Years
29%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Free Cash Flow
¥3.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
22%
|
CAGR 10-Years
10%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Free Cash Flow
-¥1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sichuan Kelun Pharmaceutical Co Ltd
Glance View
Nestled in the vibrant economic tapestry of China, Sichuan Kelun Pharmaceutical Co., Ltd. has emerged as a formidable player in the healthcare industry. Established in the late 1990s, the company embarked on its journey with a commitment to the development and production of intravenous infusion solutions. These infusion products have become the lifeblood of Kelun's operations, offering a critical healthcare solution that serves both domestic and international markets. By leveraging advanced technology and maintaining stringent quality control, Kelun ensures its offerings meet the diverse and demanding needs of modern medical practice. The company's narrative intertwines innovation with growth, as reflected in its expansive product range that has evolved to encompass antibiotics, traditional Chinese medicine, and comprehensive research in biotechnology. But Kelun's story doesn't stop there; it stands out in the pharmaceutical landscape through its integrated business model. By investing heavily in research and development, Kelun fuels its pipeline with new drugs, ensuring a steady stream of clinically effective and market-ready products. It also navigates strategic alliances and collaborations, stitching together a network that amplifies its market penetration and operational scalability. These moves not only consolidate its standing in the healthcare sector but also streamline supply chains, thereby optimizing revenues. With an agile approach that adapts to regulatory changes and market dynamics, Sichuan Kelun Pharmaceutical continues to script a narrative of resilience and business acumen in the global arena.
See Also
What is Sichuan Kelun Pharmaceutical Co Ltd's Free Cash Flow?
Free Cash Flow
2.4B
CNY
Based on the financial report for Sep 30, 2024, Sichuan Kelun Pharmaceutical Co Ltd's Free Cash Flow amounts to 2.4B CNY.
What is Sichuan Kelun Pharmaceutical Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
9%
Over the last year, the Free Cash Flow growth was -42%. The average annual Free Cash Flow growth rates for Sichuan Kelun Pharmaceutical Co Ltd have been 8% over the past three years , 9% over the past five years .
You don't have any saved screeners yet